vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2019-4-26-35vtio-1103Research ArticleТРАНСПЛАНТАЦИЯ ОРГАНОВORGAN TRANSPLANTATIONВыбывание из листа ожидания кандидатов на трансплантацию печени (делистинг) вследствие рекомпенсации хронических заболеваний печени – характеристика пациентов и предикторы делистинга в проспективном исследованииDelisting of liver transplant candidates following recompensation of chronic liver diseases – patient characteristics and predictors of delisting: a prospective studyКоробкаВ. Л.KorobkaV. L.

Ростов-на-Дону

Rostov-on-Don

ПасечниковВ. Д.PasechnikovV. D.

Пасечников Виктор Дмитриевич

355017, Ставрополь, ул. Авиационная, 21.Тел. (9624) 47-75-13

Pasechnikov Victor Dmitrievich

21, Aviatsionnaya str., Stavropol, 355017.Tel. (9624) 47-75-13

passetchnikov@mail.ruПакЕ. С.PakE. S.

Ростов-на-Дону

Rostov-on-Don

КострыкинМ. Ю.KostrykinM. Y.

Ростов-на-Дону

Rostov-on-Don

ТкачевА. В.TkachevA. V.

Ростов-на-Дону

Rostov-on-Don

БалинН. И.BalinN. I.

Ростов-на-Дону

Rostov-on-Don

ГромыкоР. Е.GromykoR. E.

Ростов-на-Дону

Rostov-on-Don

КоробкаР. В.KorobkaR. V.

Ростов-на-Дону

Rostov-on-Don

ШаповаловА. М.ShapovalovA. M.

Ростов-на-Дону

Rostov-on-Don

БабиеваА. М.BabievaA. M.

Ростов-на-Дону

Rostov-on-Don

МикутинА. В.MikutinA. B.

Ростов-на-Дону

Rostov-on-Don

АгабекянВ. С.AgabekyanV. S.

Ростов-на-Дону

Rostov-on-Don

ГБУ Ростовской области «Ростовская областная клиническая больница»; ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава РоссииРоссияRostov Regional Clinical Hospital; Rostov State Medical UniversityRussian FederationГБУ Ростовской области «Ростовская областная клиническая больница»; ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава РоссииРоссияRostov Regional Clinical Hospital; Stavropol State Medical UniversityRussian FederationГБУ Ростовской области «Ростовская областная клиническая больница»РоссияRostov Regional Clinical HospitalRussian Federation2019310120202142635Copyright © Коробка В.Л., Пасечников В.Д., Пак Е.С., Кострыкин М.Ю., Ткачев А.В., Балин Н.И., Громыко Р.Е., Коробка Р.В., Шаповалов А.М., Бабиева А.М., Микутин А.В., Агабекян В.С., 20202020Коробка В.Л., Пасечников В.Д., Пак Е.С., Кострыкин М.Ю., Ткачев А.В., Балин Н.И., Громыко Р.Е., Коробка Р.В., Шаповалов А.М., Бабиева А.М., Микутин А.В., Агабекян В.С.Korobka V.L., Pasechnikov V.D., Pak E.S., Kostrykin M.Y., Tkachev A.V., Balin N.I., Gromyko R.E., Korobka R.V., Shapovalov A.M., Babieva A.M., Mikutin A.B., Agabekyan V.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1103лист ожидания трансплантации печениделистинг вследствие рекомпенсации функции печенипредикторы делистингаliver transplant waiting listdelisting following recompensation of liver functionpredictors of delistingReferencesSamuel D, Coilly A. Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. BMC Med. 2018; 16: 113.Samuel D, Coilly A. Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. BMC Med. 2018; 16: 113.EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016; 64: 433–485.EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016; 64: 433–485.Adam R, Karam V, Cailliez V et al. Annual Report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int. 2018; 31: 1293–1317.Adam R, Karam V, Cailliez V et al. Annual Report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int. 2018; 31: 1293–1317.Adam R, Karam V, Delvart V et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012; 57: 675–688.Adam R, Karam V, Delvart V et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012; 57: 675–688.Clinical Practice EASL Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017; 66: 1047–1081.Clinical Practice EASL Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017; 66: 1047–1081.Toniutto P, Zanetto A, Ferrarese A et al. Current challenges and future directions for liver transplantation. Liver Int. 2017; 37: 317–327.Toniutto P, Zanetto A, Ferrarese A et al. Current challenges and future directions for liver transplantation. Liver Int. 2017; 37: 317–327.Koch DG, Tillman H, Durkalski V et al. Development of a Model to Predict Transplant-free Survival of Patients With Acute Liver Failure. Clin Gastroenterol Hepatol. 2016; 14: 1199–1206.Koch DG, Tillman H, Durkalski V et al. Development of a Model to Predict Transplant-free Survival of Patients With Acute Liver Failure. Clin Gastroenterol Hepatol. 2016; 14: 1199–1206.Mustian MN, Shelton BA, MacLennan PA et al. Ethnic and Age Disparities in Outcomes Among Liver Transplant Waitlist Candidates. Transplantation. 2019; 103: 1425–1432.Mustian MN, Shelton BA, MacLennan PA et al. Ethnic and Age Disparities in Outcomes Among Liver Transplant Waitlist Candidates. Transplantation. 2019; 103: 1425–1432.Bonacci M, Londono MC, Esforzado N et al. Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list. Transplant Int. 2015; 28: 1345–1349.Bonacci M, Londono MC, Esforzado N et al. Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list. Transplant Int. 2015; 28: 1345–1349.Ruiz I, Feray C, Pawlotsky JM, Hezode C. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvirbased treatment. Liver Transplant. 2015; 21: 408–409.Ruiz I, Feray C, Pawlotsky JM, Hezode C. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvirbased treatment. Liver Transplant. 2015; 21: 408–409.Belli LS, Berenguer M, Cortesi PA et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol. 2016; 65: 524–531.Belli LS, Berenguer M, Cortesi PA et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol. 2016; 65: 524–531.Aravinthan AD, Barbas AS, Doyle AC et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. Transpl Int. 2017; 30: 1140–1149.Aravinthan AD, Barbas AS, Doyle AC et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. Transpl Int. 2017; 30: 1140–1149.Wiesner R, Edwards E, Freeman R et al. United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124: 91–96.Wiesner R, Edwards E, Freeman R et al. United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124: 91–96.Wiesner R, Lake JR, Freeman RB, Gish RG. Model for end-stage liver disease (MELD) exception guidelines. Liver Transpl. 2006; 12 (12 Suppl 3): S85–877.Wiesner R, Lake JR, Freeman RB, Gish RG. Model for end-stage liver disease (MELD) exception guidelines. Liver Transpl. 2006; 12 (12 Suppl 3): S85–877.Leise MD, Kim WR, Kremers WK, Larson JJ et al. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology. 2011; 140: 1952–1960.Leise MD, Kim WR, Kremers WK, Larson JJ et al. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology. 2011; 140: 1952–1960.Volk ML, Hernandez JC, Lok AS, Marrero JA. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl. 2007; 13: 15151520.Volk ML, Hernandez JC, Lok AS, Marrero JA. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl. 2007; 13: 15151520.Коробка ВЛ, Шаповалов АМ, Данильчук ОЯ, Коробка РВ. Способ хирургического лечения и профилактики рецидива кровотечений при варикозном расширении вен пищевода и кардиального отдела желудка. Патент РФ № 2412657. http://www.freepatent.ru/images/patents/48/2412657/patent-2412657.pdf.Коробка ВЛ, Шаповалов АМ, Данильчук ОЯ, Коробка РВ. Способ хирургического лечения и профилактики рецидива кровотечений при варикозном расширении вен пищевода и кардиального отдела желудка. Патент РФ № 2412657. http://www.freepatent.ru/images/patents/48/2412657/patent-2412657.pdf.George SL, Bacon BR, Brunt EM et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009; 49: 729–738.George SL, Bacon BR, Brunt EM et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009; 49: 729–738.Mallet V, Gilgenkrantz H, Serpaggi J et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008; 149: 399–403.Mallet V, Gilgenkrantz H, Serpaggi J et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008; 149: 399–403.Roberts S, Gordon A, McLean C et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol. 2007; 5: 932–937.Roberts S, Gordon A, McLean C et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol. 2007; 5: 932–937.Afdhal N, Everson GT, Calleja JL et al. Effect of LongTerm Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension. 2015 International Liver Congress: 50th Annual Meeting of the European Association of the Study of the Liver (EASL) 2015; Abstract LP13.Afdhal N, Everson GT, Calleja JL et al. Effect of LongTerm Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension. 2015 International Liver Congress: 50th Annual Meeting of the European Association of the Study of the Liver (EASL) 2015; Abstract LP13.Belli LS, Berenguer M, Cortesi PA et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol. 2016; 65: 524–531.Belli LS, Berenguer M, Cortesi PA et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol. 2016; 65: 524–531.Perricone G, Duvoux C, Berenguer M et al. Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. Liver Int. 2018; 38: 2170–2177.Perricone G, Duvoux C, Berenguer M et al. Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. Liver Int. 2018; 38: 2170–2177.Kapoor D, Guptan RC, Wakil SM et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2000; 33: 308–312.Kapoor D, Guptan RC, Wakil SM et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2000; 33: 308–312.Yao FY, Terrault NA, Freise C et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaitingliver transplantation: a comparative study using a matched, untreated cohort. Hepatology. 2001; 34: 411–416.Yao FY, Terrault NA, Freise C et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaitingliver transplantation: a comparative study using a matched, untreated cohort. Hepatology. 2001; 34: 411–416.Nikolaidis N, Vassiliadis T, Giouleme O et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive / HBeAg negative chronic hepatitis B. Clin Transplant. 2005; 19: 321–326.Nikolaidis N, Vassiliadis T, Giouleme O et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive / HBeAg negative chronic hepatitis B. Clin Transplant. 2005; 19: 321–326.Shim JH, Lee HC, Kim KM et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010; 52: 176–182.Shim JH, Lee HC, Kim KM et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010; 52: 176–182.Jang JW, Choi JY, Kim YS, Woo HI, Choi SK, Lee CH et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus – related cirrhosis. Hepatology. 2015; 61: 18091820.Jang JW, Choi JY, Kim YS, Woo HI, Choi SK, Lee CH et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus – related cirrhosis. Hepatology. 2015; 61: 18091820.Idriss R, Hasse J, Wu T, Khan F et al. Impact of Prior Bariatric Surgery on Perioperative Liver Transplant Outcomes. Liver Transpl. 2019; 25: 217–227.Idriss R, Hasse J, Wu T, Khan F et al. Impact of Prior Bariatric Surgery on Perioperative Liver Transplant Outcomes. Liver Transpl. 2019; 25: 217–227.Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol. 2000; 95: 2936–2939.Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol. 2000; 95: 2936–2939.Shah ShA, Hayes PC, Allan PL et al. Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portal hypertension due to hepatic cirrhosis. Am J Gastroenterol. 1996; 91: 2580–2583.Shah ShA, Hayes PC, Allan PL et al. Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portal hypertension due to hepatic cirrhosis. Am J Gastroenterol. 1996; 91: 2580–2583.Li L, Duan M, Chen W et al. The spleen in liver cirrhosis: revisiting an old enemy with novel targets. J Transl Med. 2017; 15: 111.Li L, Duan M, Chen W et al. The spleen in liver cirrhosis: revisiting an old enemy with novel targets. J Transl Med. 2017; 15: 111.Alberino F, Gatta A, Amodio P et al. Nutrition and survival in patients with liver cirrhosis. Nutrition. 2001; 17: 445–450.Alberino F, Gatta A, Amodio P et al. Nutrition and survival in patients with liver cirrhosis. Nutrition. 2001; 17: 445–450.Myers RP, Tandon P, Ney M et al. Validation of the fivevariable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list. Liver Int. 2014; 34: 1176–1183.Myers RP, Tandon P, Ney M et al. Validation of the fivevariable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list. Liver Int. 2014; 34: 1176–1183.Gunsar F, Raimondo ML, Jones S et al. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther. 2006; 24: 563–572.Gunsar F, Raimondo ML, Jones S et al. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther. 2006; 24: 563–572.Vinaixa C, Strasser SI, Berenguer M. Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis: Is the Point of No Return the Same Before and After Liver Transplantation? A Review. Transplantation. 2017; 101: 916–923.Vinaixa C, Strasser SI, Berenguer M. Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis: Is the Point of No Return the Same Before and After Liver Transplantation? A Review. Transplantation. 2017; 101: 916–923.Poynard T, Moussalli J, Munteanu M et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013; 59: 675–683.Poynard T, Moussalli J, Munteanu M et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013; 59: 675–683.Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patientswith hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000; 132: 517–524.Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patientswith hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000; 132: 517–524.

The authors declare that there are no conflicts of interest present.